**INSTITUTE BIOSAFETY COMMITTEE**
**Chairperson**: Chunling Dai

# Minutes

**Institution:** New York State Institute for Basic Research in Developmental Disabilities (IBR)

**Meeting Date:** 1.21.2026

**Meeting Time:** 1:00 PM

**Meeting Type:** Virtual

**IBC Members Present:**

1. Chunling Dai (*IBC Chair*)
2. Augusta D'Amico (*IBC Member/Director of Clinical Services*)
3. Lorena Legisi-Sejdaras (*Biological Safety Officer/Director, Office of Laboratory Safety and Training*)
4. Christopher Corbo (Local Non-affiliated Member)
5. Fang Du (Lab Rep./Animal Expert)
6. Sonal Goswami (Lab Rep.)
7. Ashfaq Sheikh (Lab Rep.)
8. Wen Hu (Lab Rep./Animal Expert)
9. Karen Amble (*IBC Member/IBR Deputy Director*)
10. Xue-Ying He (Lab Rep.)
11. Michael Eisenbraun (Local Non-affiliated Member)

**IBC Members Absent:**

1. Dorota Ziemnicka (Lab Rep.)

**Quorum:** Present

**Other Individuals in Attendance:** None

**Call to Order:** 1:00 PM

**Conflicts of Interest:**

The Chair reminded all members present to identify any conflicts of interest as each registration is reviewed.

**Review and Approval of Previous Meeting Minutes:**

A member moved to approve December 22, 2025, minutes, as written. Another member seconded the motion.
The Committee voted unanimously to approve the minutes.

**Review of Prior Business:**

- Inspections of Safety Showers in the main building are in progress.

**INSTITUTE BIOSAFETY COMMITTEE**
**Chairperson**: Chunling Dai

## 2025 Annual Review:

A member moved to approve the annual updates. Another member seconded the motion. The Committee voted unanimously to approve the annual updates.

| IBC Number | NAME | PROJECT TITLE | STATUS |
|---|---|---|---|
| 2010-016 | J. Goodman | Therapeutic Intervention After Traumatic Brain Injury (TBI) | **Minor Changes**<br>1. PTZ replaced with 4-AP<br>2. Ketoprofen replaced with meloxicam<br>3. Evans blue dye and fluorescent nanoparticles added to assess blood brain barrier integrity<br>4. The therapeutic agents brivaracetam and allopregnanolone are drugs with antiepileptic properties. |

## New Applications:

- None

## New Business:

- None

## Review of Incidents:

(The NIH Guidelines require that significant incidents, violations, and research-related accidents and illnesses be reported to NIH OSP.)

- Nothing to report at this time.

## Inspections/ Ongoing:

(Section IV-B-2-b-(5) of the NIH Guidelines requires IBCs to periodically review to ensure compliance with the NIH)

- Annual inspections of IBR's main building are completed.

## Public Comments:

- There were no public comments.

## Adjournment:

A member moved to adjourn the meeting at 1:21 PM. Another member seconded the motion.